Digital Health: Does Pharma Need To Change Its Business Model To Make It Work?
This article was originally published in Scrip
Executive Summary
By 2020, pharmaceutical business models will be turned on their head because of digital health, according to a new report by the management consultancy firm Arthur D. Little (ADL).
You may also be interested in...
When The Trial Site Is A Living Room: Pharma Explores Virtual Research Options
One day in the future, clinical studies may routinely be carried out in the virtual world, with patients mostly staying put at home instead of traveling to trial sites. For now, sponsors are experimenting with new models for drug development and taking it one step at a time.
Welcome To Alexion 2.0
In an exclusive interview, Alexion R&D head John Orloff takes In Vivo on a tour around the company’s rejuvenated pipeline and explains how the business is innovating to pre-empt the Soliris-shaped hole in its balance sheet.
From US To EU: Young Biotechs Going It Alone
Europe’s patchwork of reimbursement agencies make it a daunting place for a small US biotech to do business. Traditionally large pharma partners or CMSOs have provided an experienced hand to hold, but as a new wave of gene therapies and orphan drugs get the EMA green light, smaller drug developers are applying innovation to commercialization and choosing to go solo.
Need a specific report? 1000+ reports available
Buy Reports